Vessels Sing Their ARIAs: The Role of Vascular Amyloid in the Age of Aducanumab-Reference-Cited by-同舟云学术

Vessels Sing Their ARIAs: The Role of Vascular Amyloid in the Age of Aducanumab

Published:2022-01 Issue:1 Volume:53 Page:298-302
ISSN:0039-2499
Container-title:Stroke
language:en
Short-container-title:Stroke

Author:

Sveikata Lukas¹²^ORCID,Charidimou Andreas¹,Viswanathan Anand¹^ORCID

Affiliation:

1. J. Philip Kistler Stroke Research Center, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston (L.S., A.C., A.V.).

2. Department of Clinical Neurosciences, Division of Neurology, Geneva University Hospitals and Faculty of Medicine, University of Geneva, Switzerland (L.S.).

Abstract

We review the implications of the recently approved aducanumab amyloid-β immunotherapy for treating Alzheimer disease with comorbid cerebral amyloid angiopathy. In clinical trials, amyloid-β immunotherapy has been associated with a high rate of amyloid-related imaging abnormalities, potentially driven by coexisting cerebral amyloid angiopathy. Therefore, immunotherapy’s efficacy in patients may be modified by coexisting cerebrovascular pathology. We discuss the contributions of cerebral amyloid angiopathy on the development of amyloid-related imaging abnormalities and propose strategies to identify cerebral amyloid angiopathy in patients considered for immunotherapy.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Advanced and Specialized Nursing,Cardiology and Cardiovascular Medicine,Neurology (clinical)

Link

https://www.ahajournals.org/doi/pdf/10.1161/STROKEAHA.121.036873

Reference24 articles.

1. US Food and Drug Administration (FDA). FDA’s Decision to Approve New Treatment for Alzheimer’s Disease. FDA [Internet]. https://www.fda.gov/drugs/news-events-human-drugs/fdas-decision-approve-newtreatment-alzheimers-disease.

2. Haeberlein SB Hehn C von Tian Y Chalkias S Muralidharan KK Chen T Wu S Li J Skordos L Nisenbaum Let al. EMERGE and ENGAGE Topline Results: Two Phase 3 Studies to Evaluate Aducanumab in Patients With Early Alzheimer’s Disease [Internet]. 2019 [cited 2021 Jun 9]; Available from: https://investors.biogen.com/static-files/8e58afa4-ba37-4250-9a78-2ecfb63b1dcb

3. Biogen. Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer’s Disease. Biogen [Internet]. https://investors.biogen.com/news-releases/news-release-details/biogen-and-eisai-discontinuephase-3-engage-and-emerge-trials.

4. Food and Drug Administration. Aduhelm. Highlights of Prescribing Information [Internet]. 2021 [cited 2021 Sep 1];Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761178s003lbl.pdf

5. Off-label use of aducanumab for cerebral amyloid angiopathy.;Greenberg SM;Lancet Neurol,2021

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lecanemab Blocks the Effects of the Aβ/Fibrinogen Complex on Blood Clots and Synapse Toxicity in Organotypic Culture;2024-01-21

2. Risk factors in developing amyloid related imaging abnormalities (ARIA) and clinical implications;Frontiers in Neuroscience;2024-01-19

3. Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer’s Disease;BioDrugs;2023-11-13

4. Anti-Amyloid Therapy, AD, and ARIA: Untangling the Role of CAA;Journal of Clinical Medicine;2023-10-27

5. Alzheimer's disease: From immunotherapy to immunoprevention;Cell;2023-09